Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Signed informed consent

• males aged 45-65

• insulin resistance

• central obesity

• LDL-C <6 mmol/L

• plasma triglycerides >=1.7 and ≤5.5 mmol/L

• HDL-C ≤1.2 mmol/L.

Exclusion Criteria:

• total cholesterol >7mmol/L

• pre-existing cardiovascular disease, diabetes, proteinuria or renal failure